Compare EH & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | FLGT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 867.4M |
| IPO Year | 2019 | 2016 |
| Metric | EH | FLGT |
|---|---|---|
| Price | $13.28 | $26.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $21.85 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 883.3K | 201.6K |
| Earning Date | 03-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $60,400,607.00 | ★ $315,549,000.00 |
| Revenue This Year | $10.53 | $16.84 |
| Revenue Next Year | $81.37 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.39 | 13.61 |
| 52 Week Low | $12.71 | $14.57 |
| 52 Week High | $29.76 | $31.04 |
| Indicator | EH | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 40.58 |
| Support Level | $13.18 | $27.49 |
| Resistance Level | $14.24 | $28.19 |
| Average True Range (ATR) | 0.62 | 0.72 |
| MACD | -0.09 | -0.11 |
| Stochastic Oscillator | 11.14 | 0.20 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.